Immune Check Point Inhibitors Combination in Melanoma: Worth the Toxicity?
Rev Recent Clin Trials
; 11(2): 81-6, 2016.
Article
en En
| MEDLINE
| ID: mdl-27028970
ABSTRACT
The combination of immune checkpoint inhibitors ipilimumab and nivolumab has been recently been FDA approved for first line treatment of unresectable and metastatic BRAF wild type melanoma. The approval came following the impressive results of the CheckMate 067, where the combination of ipilimumab and nivolumab appeared to outperform each as a single agent in regards to response rate and progression free survival. Though we await final overall survival data, the combination will likely be adapted by many oncologists and integrated into the ever changing melanoma treatment algorithm. In this article we aim to summarize the data leading up to the recent FDA approval and publication by Larkin et al. that presents the results from the CheckMate 067 trial. We will also further explore the feasibility, challenges, and applicability of combination immune checkpoint inhibitor therapy.
Buscar en Google
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Neoplasias Cutáneas
/
Puntos de Control del Ciclo Celular
/
Melanoma
/
Antineoplásicos
Límite:
Humans
Idioma:
En
Revista:
Rev Recent Clin Trials
Asunto de la revista:
MEDICINA
/
TERAPEUTICA
Año:
2016
Tipo del documento:
Article
País de afiliación:
Estados Unidos